House passes bill to reauthorize FDA user fee programs

Jun 09, 2022 - 02:53 PM
recissioin-legislation

The House yesterday voted 392-28 to pass legislation (H.R. 7667) that would reauthorize Food and Drug Administration user fee programs, which provide funding for the agency to review drugs, devices and biologics. Among other provisions, the bipartisan bill would include drugs on the FDA’s shortages list in a pilot program to designate advanced manufacturing technologies. The Senate Health, Education, Labor, and Pensions Committee will mark up their version of the bill Tuesday.

Related News Articles

Headline
FDA announces recall for certain IV bags
The Food and Drug Administration published a notice from Amneal Pharmaceutical that said the company is recalling two lots of its Ropivacaine Hydrochloride…
Headline
Recall issued for aspiration system by Q’Apel Medical
The Food and Drug Administration has identified a Class I recall of Q’Apel Medical 072 Aspiration System after the company submitted three device event reports…
Headline
FDA issues alerts on certain catheters produced by BD, Conavi
The Food and Drug Administration has issued alerts for issues with certain catheters made by BD and Conavi. BD identified an increase in material fatigue…
Headline
FDA recalls Medtronic Aortic Root Cannulas 
The Food and Drug Administration has identified a Class I recall of Medtronic Aortic Root Cannulas due to a risk of unexpected loose material in the male luer…
Headline
AHA blog: Can collaborative efforts to improve device design improve safety?
Despite elegant efforts to design for safe use, rigorous standards and regulatory requirements, and lots of training of health care professionals, there’s…
Blog
Can Collaborative Efforts to Improve Device Design Improve Safety?
Public
During World War II, the U.S. Army Air Corps depended on its B-17 bombers to inflict incredible damage against the Axis powers in Europe. These “Flying…